You are cordially invited to attend a program titled:

Diagnosing and Treating TA-TMA With FDA-Approved YARTEMLEA®

YARTEMLEA™ (narsoplimab-wuug) 185 mg/mL injection

PRESENTED BY

Jeff Klaus, PharmD
Barnes-Jewish Hospital
St. Louis, MO

Los Caminos Modern Cocina
880 International Pkwy
Private Dining Room
Flower Mound, TX 75022

Wednesday, June 3, 2026
6:00 PM - 8:00 PM Central

REGISTRATION
https://sphase.info/ome00084

If you have any questions, please contact
Ellen Kurtz-Hammond at (281) 788-0920 or ekurtzhammond@omeros.com.

This program is sponsored by Omeros Corporation and is not accredited.

Pursuant to the PhRMA Guidelines, as well as the policies of Omeros Corporation, attendance at this promotional program is restricted to healthcare professionals (HCPs) within the targeted specialty. Accordingly, significant others and guests are not permitted to attend this program unless they are an HCP within the targeted specialty. Consistent with applicable federal and state law disclosure requirements, the cost of meals or other items of value received may be disclosed, as determined by Omeros' Legal Department. State and federal laws and regulations may restrict state and federal employees from receiving meals. By attending this program, you confirm that you have obtained necessary approvals from your employer. HCPs may attend the program and decline a meal. Please note you are declining the meal with your registration and designate the same at the venue as you sign in for the program.

Indications and Usage

YARTEMLEA is a MASP-2 inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).

Important Safety Information for YARTEMLEA®

Contraindications

None.

Warnings and Precautions

Serious and life-threatening infections have occurred in patients treated with YARTEMLEA.

- In clinical trials in patients with TA-TMA, serious infections (regardless of causality) were reported in 36% (10/28) of patients receiving YARTEMLEA. Reported serious infections included sepsis, viral infections, pneumonia, bacteremia, fungal infection, gastroenteritis, respiratory tract infection, and urosepsis.
- If YARTEMLEA is administered to patients with active infections, monitor closely for worsening infection and treat promptly.

Adverse Reactions

The most common adverse reactions (≥20%), regardless of causality or relatedness to YARTEMLEA, were viral infections, sepsis, hemorrhage, diarrhea, vomiting, nausea, neutropenia, pyrexia, fatigue, and hypokalemia.

Use in Specific Populations

Pregnancy: Available data on the use of YARTEMLEA in pregnant women are insufficient to inform a drug-associated risk of major birth defects and miscarriage or adverse maternal or fetal outcomes.

Lactation: There are no data on the presence of YARTEMLEA in human milk, the effects on the breastfed child, or the effects on milk production.

Pediatric Use: The safety and effectiveness of YARTEMLEA for treatment of TA-TMA have been established in pediatric patients 2 years of age and older. The safety and effectiveness of YARTEMLEA have not been established in pediatric patients younger than 2 years of age.

Geriatric Use: Clinical studies of YARTEMLEA did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently than younger patients.

To report suspected adverse reactions, contact Omeros Corporation at 1-844-YARTEM1 (1-844-927-8361), or contact FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

Please see Full Prescribing Information at https://pi.omeros.com/us/yartemlea-uspi.pdf.

OMEROS